Stocktoria
Verrica Pharmaceuticals Inc. VRCA
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2018-06-15
Verrica Pharmaceuticals Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $35.6M | $7.6M | $5.1M | $9.0M | $12.0M |
| R&D expense | $8.9M | $11.8M | $20.3M | $12.2M | $15.9M |
| SG&A expense | $35.2M | $58.8M | $47.3M | $17.4M | — |
| Operating income | -$12.2M | -$65.9M | -$65.8M | -$21.3M | -$30.9M |
| Interest expense | — | — | $4.0M | $2.2M | $4.3M |
| Income tax | $0 | $0 | $0 | $0 | — |
| Net income | -$17.9M | -$76.6M | -$67.0M | -$24.5M | -$35.1M |
| EPS (diluted) | $-1.68 | $-14.78 | $-1.48 | $-0.72 | $-1.30 |
| Operating cash flow | -$17.6M | -$60.9M | -$38.6M | -$18.6M | -$27.6M |
| Free cash flow | -$17.6M | -$61.0M | -$38.9M | -$19.0M | -$28.5M |
| Cash & equivalents | $30.1M | $46.3M | $69.5M | $34.3M | $15.8M |
| Inventory | $2.2M | $2.5M | $1.0M | $0 | — |
| Total assets | $47.1M | $54.1M | $81.6M | $44.7M | $80.1M |
| Total liabilities | $22.4M | $64.0M | $61.8M | $4.7M | $47.5M |
| Shareholders' equity | $24.7M | -$9.9M | $19.8M | $40.0M | $32.6M |
Source: SEC EDGAR filings · CIK 0001660334 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.